摘要
经导管主动脉瓣置入手术自从2002年临床成功开展以来发展非常迅猛,各类技术更新层出不穷,输送器尺寸越来越小已经发展到14F,卒中比例小于4%,瓣周漏和起搏器的比例也随着临床技术经验和瓣膜产品设计更新而不断降低.而且在二叶畸形、重度钙化等领域置入技术也获得良好效果.中国经导管主动脉瓣置入手术起步较晚,但是自2017年自主知识产权瓣膜上市之后发展很快,2019年全国完成超过2000例手术,也组织发布了一些专家共识.另外一方面,国内大多数单位还处于起步阶段,经导管主动脉瓣置入手术的技术研究和推广尚待规范化的进行.
Transcatheter aortic valve implantation has been developing rapidly since it was successfully carried out in 2002.Various kinds of technical updates are emerging in endlessly.The size of the introducer sheath is becoming smaller and smaller,which has developed to 14F.The proportion of stroke is less than 4%.The proportion of perivalvular leakage and pacemaker is also decreasing with the clinical technical experience and valve product design update.In addition,the implantation technique has also achieved good results in the fields of aortic bicuspid,severe calcification and so on.China's transcatheter aortic valve implantation started late,but it has developed rapidly since the commercial available of the valves with independent intellectual property rights in 2017.In 2019,more than 2000 operations were completed nationwide,and some experts'consensus was also published.On the other hand,most of the domestic hospitals are still in the initial stage,and the technical research and promotion of transcatheter aortic valve implantation still need to be standardized.
作者
张海波
孟旭
ZHANG Hai-bo;MENG Xu(Cardiac Surgery Department of Beijing Anzhen Hospital,Capital Medical University,Beijing 100029,China)
出处
《中国心血管病研究》
CAS
2020年第4期289-294,共6页
Chinese Journal of Cardiovascular Research
